topSkip to main content

Menu, Secondary

Menu Trigger


University of Minnesota Launches COVID-19 clinical trials

Clinical trials

The University of Minnesota has launched two clinical trials to test the drug hydroxychloroquine. One trial examines the drug's effectiveness in preventing COVID-19 disease. It seeks persons who have no symptoms but have been exposed to someone with confirmed COVID-19 within four days and live in the same household with that person, or are healthcare workers or first responders.

A second trial examines the drug's effectiveness as a treatment. It seeks persons who have symptoms that started within the last four days and are not hospitalized. They must also meet at least one of the following criteria: have confirmed COVID-19 disease; live with a person with confirmed COVID-19 disease; or be a healthcare worker or first responder with a known exposure.

Hydroxychloroquine is an FDA-approved medicine for the prevention and treatment of malaria, available since the 1950s and known as Plaquenil(R). Recent work shows that hydroxychloroquine is active in a laboratory setting against the novel SARS-Cov-2 virus.

The trials are national in scope.

This story was originally posted by The University of Minnesota